Aytu Biopharma FY26 Q3 turns to $5.6 million net loss; revenue drops to $12.4 million

• Aytu BioPharma posted Q3 fiscal 2026 net loss of $5.6 million, swinging from net income of $4 million a year earlier, as net revenue fell 32.73% to $12.4 million.
• Adjusted EBITDA turned to a loss of $2.8 million from a profit of $3.9 million, reflecting planned EXXUA launch investments.
• EXXUA contributed $2.4 million in net revenue, with more than 1,300 prescriptions written by more than 450 unique prescribers during the quarter.
• Cash and cash equivalents totaled $26.7 million at March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605131605ACCESSWRNAPR_____1166230) on May 13, 2026, and is solely responsible for the information contained therein.